A structured review of clinical evidence for cannabis-based medicines in chronic pain — trial quality, effect sizes, responder rates, patient selection criteria and practical prescribing considerations for European healthcare professionals.
Chronic pain is the most common indication for medical cannabis prescribing in European markets with established programmes. This publication reviews the clinical evidence base for cannabis-based medicines in chronic pain, with a focus on evidence quality, effect sizes and practical implications for prescribing healthcare professionals.
This publication is an educational summary for healthcare professionals. It does not constitute clinical guidance or a recommendation to prescribe. Prescribing decisions should be made on the basis of individual patient assessment, current clinical guidelines and the prescribing healthcare professional's clinical judgement.
The clinical evidence for cannabis-based medicines in chronic pain has expanded substantially over the past decade, though significant limitations remain. Key characteristics of the evidence base:
A systematic review applying Cochrane methodology to 24 RCTs (n=1,334) of cannabis-based medicines in chronic non-cancer pain found statistically significant but clinically modest reductions in pain scores compared to placebo. The number needed to treat (NNT) for a 30% reduction in pain was approximately 24. Adverse events were more common in cannabis groups, primarily dizziness, sedation and cognitive effects.
A sub-analysis of neuropathic pain specifically shows somewhat stronger effects. Several trials in neuropathic pain — including those of nabiximols in multiple sclerosis-related pain and vaporised cannabis in HIV-related neuropathy — demonstrate statistically significant pain reduction versus placebo with NNTs in the range of 5–10 for a meaningful pain reduction, comparable to other second-line analgesics.
Evidence in cancer pain is limited but suggests benefit in patients with pain inadequately controlled by opioid analgesia. The combination of cannabinoids with opioids may produce opioid-sparing effects, though this is not yet robustly established in large trials.
A realistic expectation of effect size is important for both prescriber and patient:
| Outcome measure | Typical effect vs placebo | Clinical significance |
|---|---|---|
| Pain NRS (0–10 scale) | 0.5–1.5 point reduction | Below the 2-point threshold typically considered clinically meaningful; meaningful for some patients |
| 30% pain reduction (responder rate) | NNT approximately 8–24 depending on population | Comparable to other analgesics; not all patients respond |
| Sleep quality | Moderate improvement | Clinically meaningful in patients where sleep disruption is a primary complaint |
| Quality of life (various instruments) | Small to moderate improvement | Patient-reported outcomes often more positive than objective pain measures |
| Opioid sparing | Emerging evidence — not yet robustly established | Potentially significant for reducing opioid burden in chronic pain patients |
The discrepancy between modest objective pain reduction and positive patient-reported quality of life outcomes is consistently noted in the literature. This may reflect the multidimensional nature of chronic pain — cannabis may improve sleep, anxiety and general wellbeing in ways that are captured in quality of life measures but not in a single pain score.
The clinical evidence supports targeting cannabis-based medicines at patients where:
Patients with active psychosis, personal or family history of psychosis, severe hepatic impairment, or pregnancy are generally considered contraindicated. Adolescents and young adults should be treated with particular caution given evidence of adverse neurodevelopmental effects of cannabis exposure during brain development.
The principle of "start low, go slow" is well established for cannabis-based medicines. An initial dose of CBD:THC oil providing 2.5mg THC at bedtime, titrated slowly over 2–4 weeks, is a common approach. Higher THC doses may provide greater analgesia but increase the risk of adverse psychoactive effects.
Products with higher CBD:THC ratios are generally better tolerated, with less psychoactive effect. THC is considered the primary analgesic cannabinoid; CBD may modulate THC effects and has its own anti-inflammatory and anxiolytic properties. The optimal ratio for pain management has not been established by clinical evidence and is likely patient-dependent.
Oral/oromucosal administration provides more consistent and longer-lasting plasma levels than inhalation, and is the preferred route for chronic pain management. Vaporised cannabis provides faster onset and may be useful for breakthrough pain but gives less predictable dosing. Smoked cannabis is not recommended in clinical practice.
The most clinically significant adverse effects in the context of chronic pain management:
A structured monitoring approach is recommended for patients prescribed cannabis-based medicines for chronic pain:
Subscribe for new publications monthly.